Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Integrating chronic inflammation and hypoxia : the potential role of HIF-1α in tumor behavior and therapy response in high-grade serous ovarian cancer
ID
Polajžer, Sara
(
Author
),
ID
Lukanović, David
(
Author
),
ID
Škof, Erik
(
Author
),
ID
Kobal, Borut
(
Author
),
ID
Černe, Katarina
(
Author
)
PDF - Presentation file,
Download
(750,43 KB)
MD5: 1FDDDAE28717C862AE665B3E3823AF90
URL - Source URL, Visit
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1757708/full
Image galllery
Abstract
High-grade serous ovarian carcinoma (HGSOC) is marked by late diagnosis and chemoresistance, partly driven by chronic inflammation and hypoxia in the tumor microenvironment. Hypoxia-inducible factor 1-alpha (HIF-1a) is a key regulator of these processes; however, its spatial distribution, interaction with inflammation, and effect on chemotherapy response in HGSOC remain unclear. This retrospective study included 28 advanced HGSOC patients treated with neoadjuvant chemotherapy (NACT). Samples were collected at primary surgery (PS) (ovarian and peritoneal tissue, plasma, ascites) and post-NACT at interval debulking surgery (IDS) (omentum, peritoneal tissue, plasma). HIF-1a mRNA expression varied by site, with higher levels in omental and peritoneal tissues compared to ovarian tissue. Plasma and ascites concentrations were significantly correlated, although the mean ascites concentration was lower. Elevated HIF-1a concentration in ascites and plasma at baseline correlated with ESR (erythrocyte sedimentation rate) >30 mm/h, which was also correlated with BRCA mutation status. No correlation was found between HIF-1a and CRP (C-reactive protein) levels. Higher HIF-1a concentrations in ascites and plasma were linked to poor chemotherapy response (CRS1) at IDS. No significant changes in plasma HIF-1a, ESR, or peritoneal HIF-1a mRNA expression were observed before and after chemotherapy. Increased peritoneal HIF-1a at baseline showed a trend toward shorter progression-free survival. These findings suggest that HIF-1a may reflect hypoxia-inflammation crosstalk associated with chemoresistance and progression in HGSOC. The hypoxic-inflammatory microenvironment appears to persist despite chemotherapy and could contribute to ongoing disease activity. However, these observations require validation in independent cohorts before any prognostic or predictive implications can be considered.
Language:
English
Keywords:
body fluids
,
chronic inflammation
,
HIF-1a
,
high-grade serous ovarian carcinoma
,
neoadjuvant chemotherapy
,
tumor tissue
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2026
Number of pages:
10 str.
Numbering:
Vol. 17, art. 1757708
PID:
20.500.12556/RUL-181247
UDC:
616-097
ISSN on article:
1664-3224
DOI:
10.3389/fimmu.2026.1757708
COBISS.SI-ID:
271315203
Publication date in RUL:
03.04.2026
Views:
273
Downloads:
165
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Frontiers in immunology
Shortened title:
Front. immunol.
Publisher:
Frontiers Research Foundation
ISSN:
1664-3224
COBISS.SI-ID:
30774233
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
telesne tekočine
,
kronično vnetje
,
visokostopenjski serozni karcinom jajčnikov
,
neoadjuvantna kemoterapija
,
tumorsko tkivo
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P3-0067
Name:
Farmakologija in farmakogenomika
Funder:
ARIS - Slovenian Research and Innovation Agency
Funding programme:
Young researchers
Funder:
University Medical Centre Ljubljana
Project number:
20240125
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back